Abstract
Although treatment options for men with castration-resistant prostate cancer (CRPC) have improved with the recent and anticipated approvals of novel immunotherapeutic, hormonal, chemotherapeutic and bone-targeted agents, clinical benefit with these systemic therapies is transient and survival times remain unacceptably short. Thus, we devote the second section of this two-part review to discussing emerging therapeutic paradigms and research strategies that are entering phase II and III clinical testing for men with metastatic CRPC. We will discuss a range of emerging hormonal, immunomodulatory, antiangiogenic, epigenetic and cell survival pathway inhibitors in current clinical trials, with an emphasis on how these therapies may complement our existing treatment options.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 206-218 |
| Number of pages | 13 |
| Journal | Prostate Cancer and Prostatic Diseases |
| Volume | 14 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 2011 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- castrate-resistant prostate cancer
- clinical trials
- drug development
- novel therapies
Fingerprint
Dive into the research topics of 'Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS